Sugi Predict

Sugi Predict / Compounds / SCHEMBL517355

SCHEMBL517355

SCHEMBL517355

CC1C[C@H]2C(=CC1=O)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SHBG P04278 5/20 0.69
▸ SERPINA6 P08185 4/20 0.69
▸ SLC22A1 O15245 1/20 0.69
▸ ALDH1A1 P00352 1/20 0.69
▸ THRB P10828 1/20 0.69
▸ ESR2 Q92731 3/20 0.62
▸ ESR1 P03372 1/20 0.62
▸ PDK1 Q15118 2/20 0.60
▸ PDK2 Q15119 2/20 0.60
▸ PDK3 Q15120 2/20 0.60
▸ PDK4 Q16654 2/20 0.60
▸ CYP19A1 P11511 5/20 0.50
▸ AR P10275 5/20 0.50
▸ LMNA P02545 3/20 0.47
▸ HSD17B10 Q99714 3/20 0.47
▸ NR3C1 P04150 2/20 0.47
▸ PGR P06401 2/20 0.47
▸ CYP3A4 P08684 2/20 0.47
▸ TSHR P16473 2/20 0.47
▸ SNCA P37840 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16188590 1.00 SHBG (0.69) SHBGSERPINA6SLC22A1ALDH1A1THRB
SCHEMBL16741266 1.00 SHBG (0.69) SHBGSERPINA6SLC22A1ALDH1A1THRB
SCHEMBL7615553 1.00 SHBG (0.69) SHBGSERPINA6SLC22A1ALDH1A1THRB
SCHEMBL16188696 1.00 SHBG (0.69) SHBGSERPINA6SLC22A1ALDH1A1THRB
SCHEMBL3816344 0.90 SERPINA6 (0.72) SHBGSERPINA6SLC22A1ALDH1A1THRB
SCHEMBL16741272 0.85 SERPINA6 (0.71) SHBGSERPINA6SLC22A1ALDH1A1THRB
SCHEMBL1711107 0.85 SHBG (0.68) SHBGSERPINA6SLC22A1ALDH1A1THRB
SCHEMBL7705296 0.85 SERPINA6 (0.65) SHBGSERPINA6SLC22A1ALDH1A1THRB
SCHEMBL1711002 0.85 SERPINA6 (0.68) SHBGSERPINA6SLC22A1ALDH1A1THRB
SCHEMBL12615684 0.84 SERPINA6 (0.64) SHBGSERPINA6SLC22A1ALDH1A1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3612223-B1 TREATING MALE SENESCENCE NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) 2024-07-31 — — EP claimed
CN-115469036-A Method for screening and non-targeted analysis of veterinary drug suspects in food by using UPLC-HRMS 厦门海关技术中心 2022-12-13 — — CN claimed
CN-110769853-B Treatment of male aging 北京生命科学研究所 2022-06-03 — — CN claimed
US-11090307-B2 Treating male senescence NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2021-08-17 — — US claimed
EP-3612223-A1 Treating Male Senescence National Institute Of Biological Sciences, Beijing (CN) 2020-02-26 — — EP claimed
US-20200046714-A1 Treating Male Senescence NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2020-02-13 — — US claimed
WO-2018192416-A1 Treating Male Senescence NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2018-10-25 — — WO claimed
US-20120028936-A1 ORAL CONTRACEPTION WITH TRIMEGESTONE GRUNENTHAL GMBH (DE) 2012-02-02 — — US claimed
US-20100279989-A1 ORAL CONTRACEPTION WITH TRIMEGESTONE Grünenthal GmbH (DE) 2010-11-04 — — US claimed
CN-101415402-A UV-stable liquid or semisolid transdermal delivery form comprising a light-sensitive active ingredient SCHERING AKTI ENGESELLSCHAFT (DE) 2009-04-22 — — CN claimed
US-20070021396-A1 Oral contraception with trimegestone GRUNENTHAL GMBH (DE) 2007-01-25 — — US claimed
EP-1703892-A2 UV LIGHT-STABLE SEMI-SOLID TRANSDERMAL SYSTEMS COMPRISING A PHOTOSENSITIVE ACTIVE AGENT AND AN UV-ABSORBING COMPONENT Schering AG (DE) 2006-09-27 — — EP claimed
WO-2005055975-A2 UV-STABLE SEMI-SOLID TRANSDERMAL SYSTEMS COMPRISING A PHOTOSENSITIVE ACTIVE INGREDIENT AND A UV ABSORBER SCHERING AG (DE) 2005-06-23 — — WO claimed
EP-1189619-A4 ADMINISTRATION OF NON-ORAL ANDROGENIC STEROIDS TO WOMEN WATSON PHARMACEUTICALS INC (US) 2004-06-09 — — EP claimed
US-20040072808-A1 Treatment of conditions relating to hormone deficiencies by administration of progestins BARR LABORATORIES, INC. 2004-04-15 — — US claimed
EP-1390038-A2 TREATMENT OF CONDITIONS RELATING TO HORMONE DEFICIENCIES BY ADMINISTRATION OF PROGESTINS Endeavor Pharmaceuticals (US) 2004-02-25 — — EP claimed
US-20030004145-A1 Treatment of conditions relating to hormone deficiencies by administration of progestins BARR LABORATORIES, INC. 2003-01-02 — — US claimed
WO-2002092102-A2 TREATMENT OF CONDITIONS RELATING TO HORMONE DEFICIENCIES BY ADMINISTRATION OF PROGESTINS ENDEAVOR PHARMACEUTICALS (US) 2002-11-21 — — WO claimed
EP-1189619-A1 ADMINISTRATION OF NON-ORAL ANDROGENIC STEROIDS TO WOMEN Watson Pharmaceuticals, Inc. (US) 2002-03-27 — — EP claimed
WO-2000076522-A1 ADMINISTRATION OF NON-ORAL ANDROGENIC STEROIDS TO WOMEN WATSON PHARMACEUTICALS, INC. (US) 2000-12-21 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11090307-B2 Treating male senescence RIPK3, RIPK1, MLKL SHBG 293/4885SERPINA6 4024/4885SLC22A1 4608/4885
US-20200046714-A1 Treating Male Senescence RIPK3, RIPK1, MLKL SHBG 293/4885SERPINA6 4024/4885SLC22A1 4608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback